Browse EX-10 agreements

LOAN ASSIGNMENT AND ASSUMPTION AGREEMENT

 

This LOAN ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made and entered into as of May , 2026 (the “Effective Date”), by and between DATZ WORLD HOLDINGS CORP., a Nevada corporation formerly known as Leafbuyer Technologies, Inc. (“Assignor”), and LB Media Group LLC, a Colorado limited liability company (“Assignee”). Kurt Rossner, Mark Breen, and Michael Goerner (collectively, the “Guarantors”) are executing this Agreement for the purposes set forth herein.

 

RECITALS

 

WHEREAS, Assignor is the borrower under that certain U.S. Small Business Administration (the “SBA Lender”) Economic Injury Disaster Loan, dated as of April 30, 2020, having an initial principal amount equal to $500,000 (“SBA Loan”);

 

Whereas, the Guarantors each executed and delivered to the Lender one or more guaranties pursuant to which such Guarantors guaranteed the obligations of Assignor with respect to the Loan;

…

NOTE EXCHANGE AGREEMENT

 

This NOTE EXCHANGE AGREEMENT, dated May 28 2026 (this “Agreement”), is among DATZ World Holdings Corp., a Nevada corporation (the “Seller” or the “Company”), Jeff Bishop (“Bishop”), Allan Marshall (“Allan”) and MFA Holdings, Corp., a Florida corporation (“MFA and together with Allan, the “Lenders”).

 

W I T N E S S E T H:

 

WHEREAS, on September 18, 2018, the Company made a convertible promissory note in favor of Bishop in the original principal amount of Two Hundred Twenty Thousand Dollars ($220,000) with a maturity date of September 21, 2019, with interest at the rate of ten percent (10%) which remains unpaid as of the date hereof and has accrued interest in the amount of $190,749.41 as of the date hereof (“Loan 1”);

…

June 8, 2026

 

Dear Christiane:

 

This Director Offer Letter sets forth the terms and conditions of your appointment to serve as a director (“Director”) on the board of directors (the “Board”) of Shake Shack Inc. (the “Company”) and to serve as a member of the Nominating & Corporate Governance Committee of the Board (the “Committee”), effective as of July 2, 2026 (the “Effective Date”).

 

As a Director, you will be expected to attend at least four (4) Board and four (4) Committee meetings each service year1 and shall have such other duties and responsibilities as are customarily associated with this position. You will serve on the Board until such time that either you or the Company terminates your service or unless you are not re-elected to the Board at the Annual General Meeting of Stockholders in June 2029.

…

Document

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601 (b)(10)

Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

AMENDMENT NO. 7

AMENDMENT NO. 7, dated as of June 10, 2026 (this “Amendment”), is by and among SHOALS TECHNOLOGIES GROUP, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, WILMINGTON TRUST, NATIONAL ASSOCIATION, as collateral agent (in such capacity, the “Collateral Agent”), JPMORGAN CHASE BANK, N.A. (“JPMorgan”), as administrative agent (in such capacity, the “Administrative Agent”), and the 2026 Incremental Revolving Lenders (as defined below).

W I T N E S S E T H:

…

321452236 v8

 

 

Vor Biopharma Inc.

Amended and Restated 2021 Equity Incentive Plan

Adopted by the Board of Directors: April 16, 2026

Approved by the Stockholders: June 11, 2026

 

 

 

---

321452236 v8

 

Table of Contents

 

Page

 

1. General.

1

2. Shares Subject to the Plan.

1

3. Eligibility and Limitations.

2

4. Options and Stock Appreciation Rights.

3

5. Awards Other Than Options and Stock Appreciation Rights.

7

6. Adjustments upon Changes in Common Stock; Other Corporate Events.

9

7. Administration.

11

8. Tax Withholding

14

9. Miscellaneous.

15

10. Covenants of the Company.

18

11. Additional Rules for Awards Subject to Section 409A.

18

12. Severability.

22

13. Termination of the Plan.

22

14. Definitions.

23

 

 

i.

 

 

---

321452236 v8

 

 

1. General.

…

TRANSITION AGREEMENT

This Transition Agreement ("Agreement") is entered into as of June 11, 2026 (the "Effective Date"), by and between NN, INC., a Delaware corporation (the "Company") and JAMI STATHAM ("Statham"). Each of the Company and Statham may be referred to as a "Party" and, collectively, as the "Parties".

Background

WHEREAS, the Company and Statham are parties to that certain Letter of Understanding, dated June 5, 2024 (the “LOU”) pursuant to which the Company employs Statham;

 

WHEREAS, the Company and Statham are parties to that certain Separation Agreement, dated July 8, 2024 (the “Separation Agreement”); and

 

WHEREAS, Statham’s employment with the Company will end by mutual agreement on the Separation Date (as defined below) under circumstances that the Parties agree will not entitle Statham to receive any severance payments under the terms of the Separation Agreement.

 

Agreement

…

Document

Exhibit 10.3

Name:

Number of Shares of Stock subject to the Stock Option:

Exercise Price Per Share:

$

Date of Grant:

[Vesting Commencement Date:]

CAMP4 THERAPEUTICS CORPORATION 2026 INDUCEMENT PLAN

NON-STATUTORY STOCK OPTION AGREEMENT

This agreement (this “Agreement”) evidences a stock option (the “Stock Option”) granted by CAMP4 Therapeutics Corporation (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the CAMP4 Therapeutics Corporation 2026 Inducement Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

…

Document

Exhibit 10.1

Amendment No. 1 to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan

In accordance with Section 9 of the CAMP4 Therapeutics Corporation (the “Company”) 2024 Equity Incentive Plan (the “Plan”), the Plan is hereby amended as follows, subject to approval of the Company’s stockholders:

1.The second sentence of Section 4(a) of the Plan is hereby deleted and replaced as follows:

The Initial Share Pool will automatically increase on January 1 of each year during the term of the Plan, beginning in 2025, by the lesser of (i) five percent (5%) of the Outstanding Shares as of the close of business on the immediately preceding December 31, and (ii) the number of shares of Stock determined by the Board on or prior to such date for such year (the Initial Share Pool, as it may be so increased, the “Share Pool”).

2.Exhibit A of the Plan is hereby amended to include the following as a new defined term:

…

Document

Exhibit 10.2

CAMP4 THERAPEUTICS CORPORATION 2026 INDUCEMENT PLAN

1.DEFINED TERMS

Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to those terms.

2.PURPOSE

The Plan has been established to allow the Company to provide an inducement to secure and retain the services of Eligible Individuals (as defined in Section 5) by providing for the grant of Awards to such Eligible Individuals. This Plan is intended to meet the requirements of a plan providing for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules and shall be administered in accordance with such intent.

3.ADMINISTRATION

…

AMENDMENT NO. 2 TO

THE OPTIMIZERX CORPORATION

2021 EQUITY INCENTIVE PLAN

Dated: June 9, 2026

 

WHEREAS, the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”) established the OptimizeRx Corporation 2021 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Board desires to amend the Plan to increase the maximum number of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) available for grants of Awards thereunder by 1,000,000 shares to 5,450,000 shares, as of the date on which shareholders of the Company approve this amendment; and

 

WHEREAS, Section 12(c) of the Plan authorizes the Board to amend the Plan, subject to shareholder approval to the extent that such approval is desired or required by applicable law;

 

NOW, THEREFORE, effective the date hereof, the Plan is hereby amended as follows:

 

Subject to approval of the Company’s shareholders, Section 3(a) of the Plan is hereby amended and restated in its entirety, to read as follows:

…

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF APRIL 20, 2026)

 

ARTICLE One GENERAL PROVISIONS

 

I.

PURPOSES OF THE PLAN

 

A.                This Stock Incentive Plan (the “Plan”), formerly the “BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,” is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), by providing a method whereby (i) employees (including officers and directors) of the Company (or its parent or subsidiary corporations), (ii) non-employee members of the board of directors of the Company (the “Board”) (or of any parent or subsidiary corporations) and (iii) consultants and other independent contractors who provide valuable services to the Company (or any parent or subsidiary corporations) may be offered the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company as an incentive for them to remain in the service of the Company (or any parent or subsidiary corporations).

…